C. Boyd Clarke

Biography

Mr. Clarke’s original training in the pharmaceutical and vaccine industry was received at Merck and Company, where he held positions, including Vice President of the Merck Vaccine Division and the founding President of Pasteur-Merieux MSD, a European joint venture that commercialized vaccines in the European Union. Since leaving Merck in 1996, his career has focused on leading and advising smaller developmental biotechnology and vaccine companies. Mr. Clarke was previously President and Chief Executive Officer of three biotechnology companies: Neose Technologies, a protein therapeutics company; Aviron, a vaccine company; and U.S. Bioscience, an oncology company. MedImmune acquired both Aviron (in 2001) and U.S. Bioscience (in 1999) for a combined value of $2 billion. Mr. Clarke has served as Chairman of the Board of QLT (an ocular company) and Mersana Therapeutics (an oncology company), and as Executive Chairman of LigoCyte Pharmaceuticals (a vaccine company), in which he oversaw the sale of the company to Takeda Pharamceuticals in 2012. He also served as a Board member or advisor to several other smaller companies. In these capacities, he has developed significant expertise in the challenges of small company leadership, strategic management, business development, and mergers and acquisitions.

Research Interest

Her research interests include fields like vaccines and Medical Devices